Late radiation fibrosis and chronic post-RT skin change
Chronic radiation dermatitis; late radiation skin change; radiation poikiloderma; RT-induced fibrosis
Late radiation skin change develops months to decades after radiotherapy and includes telangiectasia, hyperpigmentation and / or hypopigmentation, atrophy, fibrosis, alopecia in hair-bearing areas, and chronic xerosis. Late effects are dose- and volume-dependent and largely irreversible. Beyond cosmetic and functional implications, the irradiated field is at lifelong risk of secondary cutaneous malignancy — BCC, cSCC, sarcoma (AFX, PDS, angiosarcoma, Stewart-Treves variant of angiosarcoma in chronic lymphoedema). Surveillance of irradiated skin is therefore an integral component of long-term cancer follow-up.
Clinical features
- Telangiectasia — fine vascular ectasia within the field; often distinguishable from spontaneous telangiectasia by sharp field borders.
- Hyperpigmentation / hypopigmentation — mottled change especially in Fitzpatrick IV–VI skin; can mimic poikiloderma.
- Atrophy — thin, shiny epidermis with prominent vasculature.
- Fibrosis — induration, loss of skin elasticity, restricted range of motion in adjacent joints, chronic lymphoedema.
- Alopecia — permanent at doses ≥ 45 Gy; usually scarring.
- Xerosis — chronic dryness, pruritus.
- Onset 6 months to many years after RT; progression continues over decades.
Secondary cutaneous malignancy in irradiated skin
- BCC and cSCC — common; latency 5–30 years after RT.
- Atypical vascular lesion — post-RT precursor of angiosarcoma; characterised by MYC negativity (in contrast to MYC-amplified angiosarcoma); see AVL.
- Cutaneous angiosarcoma — post-RT angiosarcoma is one of the better-characterised RT-induced sarcomas; latency 4–10 years on average; aggressive; MYC amplification on FISH.
- Stewart-Treves syndrome — angiosarcoma in chronic lymphoedema (post-mastectomy, post-RT).
- AFX / PDS / undifferentiated pleomorphic sarcoma — increased risk in irradiated skin.
- Any new lesion in an irradiated field warrants biopsy without delay.
Management
- Daily emollients and gentle skin care are the mainstay.
- Pentoxifylline + vitamin E — modest evidence for reducing established radiation fibrosis (PENTOCLO regimen).
- Camouflage make-up for cosmetic issues.
- Pulsed dye laser for symptomatic / cosmetically distressing telangiectasia.
- Hyperbaric oxygen therapy in selected cases of refractory soft-tissue radionecrosis.
- Lymphoedema management — manual lymphatic drainage, compression — for chronic post-axillary RT lymphoedema.
- Scar / fibrosis-related joint contracture — physiotherapy, occupational therapy.
Surveillance
- Lifelong skin examination of the irradiated field — annual at minimum, more often for high-risk patients (childhood RT survivors, prior cSCC field).
- Educate the patient about photoprotection of the irradiated skin and self-examination.
- Low threshold for biopsy of any new lesion — bruise-like patches, violaceous papules, indurated nodules.
- Document the field and dose at baseline so future tumours can be attributed correctly.
References
- Delanian S, Lefaix JL. Current management for late normal-tissue injury — pentoxifylline and vitamin E. Cancer Radiother; 2007.
- Spalek M. Chronic radiation-induced dermatitis — challenges and solutions. Clin Cosmet Investig Dermatol; 2016.
- Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment. J Am Acad Dermatol. 2006;54(1):28-46.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.